Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

645148.pdf (1.18 MB)

Document type

Article

Version

Published version

Publication date

2014-11-14

Publication license

cc-by-nc (c) García-Albéniz, X. et al., 2014
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/111525

Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3748/wjg.v20.i42.15820

Abstract

AIM: To evaluate the long-term results of conventional chemoradiotherapy and laparoscopic mesorectal excision in rectal adenocarcinoma patients without adjuvant therapy. METHODS: Patients with biopsy-proven adenocarcinoma of the rectum staged cT3-T4 by endoscopic ultrasound or magnetic resonance imaging received neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy. Laparoscopic surgery was planned after 5-8 wk. Patients diagnosed with ypT0N0 stage cancer were not treated with adjuvant therapy according to the protocol. Patients with ypT1-2N0 or ypT3-4 or N+ were offered 5-fluorouracil-based adjuvant treatment on an individual basis. An external cohort was used as a reference for the findings. RESULTS: One hundred and seventy six patients were treated with induction chemoradiotherapy and 170 underwent total mesorectal excision. Cancer staging of ypT0N0 was achieved in 26/170 (15.3%) patients. After a median follow-up of 58.3 mo, patients with ypT0N0 had five-year disease-free and overall survival rates of 96% (95%CI: 77-99) and 100%, respectively. We provide evidence about the natural history of patients with localized rectal cancer achieving a complete response after preoperative chemoradiation. The inherent good prognosis of these patients will have implications for clinical trial design and care of patients. CONCLUSION: Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision might be safe within an experienced multidisciplinary team.

Subject

Càncer colorectal, Radioteràpia, Quimioteràpia del càncer, Cirurgia laparoscòpica, Estudi de casos

Subject (English)

Colorectal cancer, Radiotherapy, Cancer chemotherapy, Laparoscopic surgery, Case studies

Citation

Collections

Articles publicats en revistes (Fonaments Clínics)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Citation

GARCÍA-ALBÉNIZ, Xavier, et al. Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World Journal of Gastroenterology. 2014. Vol. 20, num. 42, pags. 15820-15829. ISSN 1007-9327. [consulted: 7 of August of 2026]. Available at: https://hdl.handle.net/2445/111525

Export metadata

JSON - METS

Share record